ICD-10 Coding for Breast Fibrocystic Disease(C50.911U, N60.19, N60.19B)
Comprehensive guide on ICD-10 coding for breast fibrocystic disease, including documentation requirements and common coding pitfalls.
Complete code families applicable to Breast Fibrocystic Disease
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| N60.19 | Diffuse cystic mastopathy | Use when documentation confirms diffuse cystic changes without specific mention of fibrosclerosis or epithelial proliferation. |
|
| N60.3 | Fibrosclerosis of breast | Use when documentation specifies fibrosclerosis with epithelial proliferation. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutBreast Fibrocystic Disease
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Breast Fibrocystic Disease.
Omitting laterality in documentation
Impact
Clinical: Potential for incorrect treatment planning., Regulatory: Non-compliance with ICD-10 coding rules., Financial: Denied claims due to insufficient specificity.
Mitigation
Always document the affected breast(s)., Use templates that prompt for laterality.
Using malignant codes for benign conditions
Impact
Reimbursement: Incorrect DRG assignment leading to potential overpayment., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data affecting patient records.
Mitigation
Verify histologic findings before coding as malignant.
Incorrect use of malignant codes
Impact
Using C50 codes for benign conditions like fibrocystic disease.
Mitigation
Ensure biopsy results confirm malignancy before using C50 codes.